Financial Results
Tejnaksh Healthcare Reports Q2 FY27 Results
Tejnaksh Healthcare submitted unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, with limited review reports.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Bearish
8
Neutral
2
Bullish
4
Bearish
10
Neutral
2
Bullish
34
Bearish
2
Neutral
0
Bullish
30
Bearish
2
Neutral
0
Bullish
30
Bearish
2
Neutral
0
Bullish
30
Bearish
2
Neutral
0
Bullish
30
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q4 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Investor Presentation
Q1 FY26
Investor Presentation
Q4 FY25
Investor Presentation
Q3 FY18
Healthcare Services
Healthcare Service Provider
28 Cr
Low Risk
18.2
59.7
-1.8
1.0
18.54
10.65
Sales CAGR
Profit CAGR
ROE
ROCE

Tejnaksh Healthcare Ltd (TEJNAKSH) is currently trading at 13.79 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Tejnaksh Healthcare Limited is a regionally focused healthcare operator that runs a super‑specialty Institute of Urology in Dhule and operates a network of clinics and hospitals, including 13 urology clinics, 4 urology hospitals and 2 dental speciality clinics, with a subsidiary Tej Vedaant Healthcare Private Limited supporting consolidated operations and teaching activities. The company reported modest quarterly profitability for the period ended June 30, 2026, with standalone profit before tax of ₹45.10 lakhs and profit after tax of ₹29.11 lakhs, while consolidated profit after tax was reported at approximately ₹26.07 lakhs; the statutory auditor issued an unmodified limited review opinion on these interim results. A material non‑operating accounting item influenced the quarter: the Group remeasured gratuity liability due to India’s New Labour Codes (effective November 21, 2025), resulting in a reversal of gratuity liability recognised as other income, which meaningfully supported reported profitability in the quarter. Tejnaksh operates in a single reportable segment—Medical and Healthcare Services—with a clear social mission to provide affordable, super‑specialty urology care to the Khandesh region, while maintaining teaching and training capabilities including an indigenous PCNL simulation lab and recognized training programmes by national bodies. The company remains compactly capitalised with paid‑up equity share capital of ₹1,015.68 lakhs and low per‑share earnings; this scale implies concentrated regional exposure, limited financial cushion for large investments, and heightened sensitivity to regulatory, reimbursement, or patient‑volume swings.
Over the past 52 weeks, Tejnaksh Healthcare Ltd has traded between a low of ₹10.65 and a high of ₹18.54. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Tejnaksh Healthcare Ltd has a market capitalization of approximately 28.01. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Tejnaksh Healthcare Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 18.19 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 28.01 Cr, Tejnaksh Healthcare Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Tejnaksh Healthcare Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Tejnaksh Healthcare Ltd is 18.19. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Profit attributable to equity holders of Tejnaksh Healthcare was Rs 56.90 lakh for the quarter ended September 30, 2026. Non-controlling interests accounted for Rs 6.95 lakh, taking total consolidated profit to Rs 63.85 lakh. Total comprehensive income attributable to equity holders was Rs 57.53 lakh.
Tejnaksh Healthcare reported consolidated profit of Rs 63.85 lakh for the quarter ended September 30, 2026. The comparable profit for the quarter ended September 30, 2025 was Rs 33.15 lakh. Profit before tax increased to Rs 74.88 lakh from Rs 48.53 lakh.
Tejnaksh Healthcare Limited will hold its board meeting on November 12, 2026. The company said the board will consider unaudited standalone and consolidated results for Q2 FY27, covering July to September 2026.
Financial Results
Tejnaksh Healthcare submitted unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, with limited review reports.
Financial Results
Tejnaksh Healthcare approved unaudited standalone and consolidated financial results for the quarter ended September 30, 2026, and noted the limited review report.